Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
PRIM-DJ2727 in NAFLD
NCT04371653Phase 2Withdrawn
- Sponsor
- UTHealth Houston
- Start
- Dec 2023
- Primary completion
- Dec 2024
- Modality
- Microbiome Therapeutics
01
Overview
A Phase 2 trial of PRIM-DJ2727 in non-alcoholic fatty liver disease (NAFLD), sponsored by UTHealth Houston. Planned start Dec 2023; status: withdrawn.
02
Drugs
PRIM-DJ2727
03
Conditions
non-alcoholic fatty liver disease (NAFLD)
Beyond the preview
Go deeper on NCT04371653.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT04371653.